Home › Targets › IKZF3

IKZF3 (2 companies · 6 programs)

Companies with an active program directed at IKZF3.

Nurix Therapeutics, Inc. NRIX

zelebrudomide — Diffuse Large B-Cell Lymphoma Phase 1
zelebrudomide — Mantle Cell Lymphoma Phase 1
zelebrudomide — Chronic Lymphocytic Leukemia Phase 1
zelebrudomide — Marginal Zone Lymphoma Phase 1
zelebrudomide — Waldenström's Macroglobulinemia Phase 1

C4 Therapeutics, Inc. CCCC

cemsidomide — Multiple Myeloma Phase 2